One mechanistic target that has been identified for treating MASLD is fibroblast growth factor 21 (FGF-21), which is involved in ferroptosis, a process that in the liver has recently gained attention due to its implications in metabolic disease (113). The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.